How does bortezomib's inhibition of the 26S proteasome lead to cancer cell death?

Bortezomib inhibits the 26S proteasome’s chymotrypsin-like activity, preventing targeted degradation of ubiquitinated proteins and disrupting signalling pathways, including regulation of cell-cycle progression and NF-kB activation, ultimately causing cell-cycle arrest and apoptosis (cancer cell death).